Active Ingredient: Nelarabine
Nelarabine is indicated for the treatment of patients with T-cell acute lymphoblastic leukaemia (T-ALL) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.
For this indication, competent medicine agencies globally authorize below treatments:
1,500 - 1,500 mg per m² of body surface area (BSA)
From 1,500 To 1,500 mg per m² of body surface area (BSA) once every 2 day(s) for 5 day(s)
The recommended dose of nelarabine for adults and adolescents aged 16 years and older is 1,500 mg/m² administered intravenously over two hours on days 1, 3 and 5 and repeated every 21 days.
Nelarabine must be discontinued at the first sign of neurological events of National Cancer Institute Common Terminology Criteria Adverse Event (NCI CTCAE) grade 2 or greater. Delaying subsequent dosing is an option for other toxicities, including haematological toxicity.
It should be administered intravenously as a two-hour infusion.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.